Improved outcomes in patients with non-variceal upper gastrointestinal bleeding while undergoing antithrombotic therapy: A propensity score matching analysis.

Autor: Acehan F; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey. Electronic address: acehanf@gmail.com., Karsavuranoğlu B; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Aslan M; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Kalkan C; Department of Gastroenterology, Ankara City Hospital, Ankara, 06800, Turkey., Sahiner ES; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Inan O; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Comoglu M; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Yilmaz Y; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey., Ates I; Department of Internal Medicine, Ankara City Hospital, Ankara, 06800, Turkey.
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Nov; Vol. 56 (11), pp. 1854-1862. Date of Electronic Publication: 2024 May 15.
DOI: 10.1016/j.dld.2024.04.038
Abstrakt: Background: This study sought to examine the effect of antithrombotic use on clinical outcomes in non-variceal upper gastrointestinal bleeding (UGIB).
Methods: Patients consecutively diagnosed with non-variceal UGIB between February 2019 and September 2020 were divided into two groups based on their antithrombotic use: users and non-users. Using propensity score matching (PSM) and multivariable regression analyses, the impact of antithrombotic use prior to UGIB presentation on clinical outcomes was examined.
Results: In the entire cohort, there were 210 and 260 patients in the antithrombotic user and non-user groups, respectively. Using PSM analysis with seven covariates, two matched groups of 157 patients were created at a 1:1 ratio. In the matched cohort, despite their longer hospital stays and a higher rate of intensive care unit admissions, the patients in the user group had lower 30- and 90-day mortality rates (4.5% vs. 14.0 %; p = 0.003 and 8.9% vs. 18.5 %; p = 0.014, respectively). In the entire cohort, multivariable analyses adjusted for confounding factors revealed that antithrombotic use was associated with lower risks of in-hospital (adjusted OR: 0.437; 95 % CI: 0.191-0.999), 30-day (adjusted OR: 0.261; 95 % CI: 0.099-0.689), and 90-day (adjusted OR: 0.386; 95 % CI: 0.182-0.821) mortality.
Conclusion: Antithrombotic use prior to UGIB presentation was found to be an independent protective factor for all-cause mortality.
Competing Interests: Conflict of interest The authors have no conflict of interest to disclose.
(Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: